LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company specializing in novel cancer therapies, announced today that it has engaged IBN, a multifaceted financial news and publishing company, to support its corporate communications strategy. The partnership aims to leverage IBN's extensive distribution platform, which includes over 5,000 syndication outlets, newsletters, social media channels, blogs, and wire services via InvestorWire, to increase awareness of LIXTE's first-in-class approach to enhancing the effectiveness of existing chemotherapy and immunotherapy treatments.
LIXTE's lead clinical candidate, LB-100, is a PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. According to the company, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, based on extensive published preclinical data available at www.lixte.com. The compound is part of a pioneering effort in an entirely new field of cancer biology—activation lethality—covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently ongoing for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The engagement with IBN is expected to amplify LIXTE's corporate communications, utilizing IBN's dynamic brand portfolio that includes TinyGems, a platform focused on innovative small-cap and mid-cap companies. Through this collaboration, LIXTE aims to reach a wider audience of investors, influencers, and the general public, thereby enhancing its brand recognition in the competitive biotech landscape.
For more information on LIXTE's latest updates, investors can visit the company's newsroom at https://ibn.fm/LIXT. The full press release is available at https://ibn.fm/wlINV.
